Q&A: Inovio CEO on DNA Vaccines
Thursday, February 21, 2013
One area of biotechnology that has drawn a lot of attention in recent years is DNA vaccines. Unlike traditional vaccination that uses an infectious agent (such as a weakened version of a virus) to stimulate the immune system, DNA vaccination tries to generate immune responses by injecting genetically engineered DNA molecules into body tissues.
Pennsylvania-based Inovio Pharmaceuticals Inc. INO -4.55% specializes in DNA vaccines. Many of its vaccines – for cancers, leukemia, hepatitis C and other diseases — are in mid-stage clinical testing phases.
Inovio Chief Exeucitive Joseph Kim, who is attending The Wall Street Journal’s Unleashing Innovation conference in Singapore this week, shared his views on the future of DNA vaccines.
- Health Care
- public health